Melinda Herbath

Dr. Melinda Herbath

University of Wisconsin-Madison
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MHMartin Hsu
Martin Hsu
CLCollin Laaker
Collin Laaker
AMAndy Madrid
Andy Madrid
MHMelinda Herbath
Melinda Herbath
YCYun Hwa Choi
Yun Hwa Choi
ZFZsuzsanna Fabry
Zsuzsanna Fabry

1 May 2019 in Cell Reports
Verified
Journal Article
Open access
JHJeffrey S. Harding
Jeffrey S. Harding
MHMelinda Herbath
Melinda Herbath
YCYuli Chen
Yuli Chen
ARAditya Rayasam
Aditya Rayasam
ARAnna Ritter
Anna Ritter
MSMatyas Sandor
Matyas Sandor
Many autoimmune and infectious diseases are characterized by the formation of granulomas which are inflammatory lesions that consist of spatially organized immune cells. These sites protect the host and control pathogens like Mycobacterium tuberculosis (Mtb), but are highly inflammatory and cause pathology. Using bacille Calmette-Guerin (BCG) and Mtb infection in mice that induce sarcoid or caseating granulomas, we show that a subpopulation of granuloma macrophages produces vascular endothelial growth factor (VEGF-A), which recruits immune cells to the granuloma by a non-angiogenic pathway. Selective blockade of VEGF-A in myeloid cells, combined with granuloma transplantation, shows that granuloma VEGF-A regulates granulomatous inflammation. The severity of granuloma-related inflammation can be ameliorated by pharmaceutical or genetic inhibition of VEGF-A, which improves survival of mice infected with virulent Mtb without altering host protection. These data show that VEGF-A inhibitors could be used as a host-directed therapy against granulomatous diseases like tuberculosis and sarcoidosis, thereby expanding the value of already existing and approved anti-VEGF-A drugs.

4 December 2019 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
NMN Mihaylova
N Mihaylova
PCP Chipinski
P Chipinski
SBS Bradyanova
S Bradyanova
TVT Velikova
T Velikova
EIE Ivanova-Todorova
E Ivanova-Todorova
ATAndrey Tchorbanov
Andrey Tchorbanov

12 December 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
YCYun Hwa Choi
Yun Hwa Choi
MHMartin Hsu
Martin Hsu
CLCollin Laaker
Collin Laaker
JPJenna Port
Jenna Port
KKKristóf G. Kovács
Kristóf G. Kovács
ZFZsuzsanna Fabry
Zsuzsanna Fabry
Cerebrospinal fluid (CSF), antigens, and antigen-presenting cells drain from the central nervous system (CNS) into lymphatic vessels near the cribriform plate and dura, yet the role of these vessels during stroke is unclear. Using a mouse model of ischemic stroke, transient middle cerebral artery occlusion (tMCAO), we demonstrate stroke-induced lymphangiogenesis near the cribriform plate, peaking at day 7 and regressing by day 14. Lymphangiogenesis is restricted to the cribriform plate and deep cervical lymph nodes and is regulated by VEGF-C/VEGFR-3 signaling. The use of a VEGFR-3 inhibitor prevented lymphangiogenesis and led to improved stroke outcomes at earlier time points, with no effects at later time points. VEGF-C delivery after tMCAO did not further increase post-stroke lymphangiogenesis, but instead induced larger brain infarcts. Our data support the damaging role of VEGF-C acutely and a pro-angiogenic role chronically. This nuanced understanding of VEGFR-3 and VEGF-C in stroke pathology advises caution regarding therapeutic VEGF-C use in stroke.

27 June 2025 in Science Advances
Verified
Journal Article
Open access
CLCollin J. Laaker
Collin J. Laaker
KKKristof G. Kovacs
Kristof G. Kovacs
CBCameron M. Baenen
Cameron M. Baenen
MHMartin Hsu
Martin Hsu
JPJenna M. Port
Jenna M. Port
ZFZsuzsanna Fabry
Zsuzsanna Fabry
Cerebrospinal fluid (CSF) contains inflammatory cues that enable peripheral immune surveillance of the central nervous system (CNS). While some cranial nerves allow for CSF efflux, the immune environment around CSF-interfacing cranial nerves during neuroinflammation is still poorly understood. Using a mouse model of multiple sclerosis [experimental autoimmune encephalomyelitis (EAE)] and CNS Mycobacterium tuberculosis infection (CNS-Mtb), we examined immune responses around olfactory nerve bundles near the cribriform plate, a key CSF efflux route. During neuroinflammation, we found increased perineural immune cells that had access to intracranial injected beads, dye, and bacteria. Additionally, we identified osseous channels connecting the environment surrounding olfactory nerves to bone marrow in the cribriform plate (cpBM). Notably, the cpBM undergoes myelopoiesis during EAE, has access to components of intracranial drainage, and is vulnerable to Mtb bacteria invasion during CNS-Mtb infection. Our findings improve the understanding of how the environments of CSF-interfacing cranial nerves and bone marrow are altered within the skull during neuroinflammatory disease.

16 March 2017 in Autoimmunity
Verified
Journal Article
Closed access
NMNikolina Mihaylova
Nikolina Mihaylova
SBSilviya Bradyanova
Silviya Bradyanova
PCPetroslav Chipinski
Petroslav Chipinski
MHMelinda Herbath
Melinda Herbath
SCStela Chausheva
Stela Chausheva
ATAndrey Tchorbanov
Andrey Tchorbanov
Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy. Annexin A1 (ANX A1) is expressed by many cell types and binds to phospholipids in a Ca2+ dependent manner. Abnormal expression of ANX A1 was found on activated B and T cells in both murine and human autoimmunity, suggesting its potential role as a therapeutic target. While its role on T lymphocytes is through formyl peptide receptor-like molecules (FPRL), and the formed ANX A1/FPRL pathway modulates T cell receptor signalling, there is still no fool-proof data available for the role of ANX A1 in B cells. We employed a lupus model of Balb/c mice with pristane-induced SLE which very closely resembles human lupus. In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody. Administration of this monoclonal antibody resulted in the inhibition of T-cell activation and proliferation, suppression of IgG anti-dsDNA antibody-secreting plasma cells and of proteinuria, decreased disease activity and prolonged survival compared to control group.